Treatment of Danhong Injection Combined with Naoxintong Capsule in Acute Coronary Syndrome Patients Undergoing PCI Operation: Study for a Randomized Controlled and Double-Blind Trial
Table 3
Comparison of secondary outcomes between the treatment and control groups.
Treatment
Control
Subjects,
65
65
NO, μmol/L
Baseline
52.57 ± 3.27
53.10 ± 2.84
−0.978
0.330
Day 7
62.79 ± 3.04
60.71 ± 2.53
4.225
≤0.001
Week 12
73.86 ± 4.37
69.12 ± 2.52
7.581
≤0.001
ET-1, ng/L
Baseline
124.26 ± 3.56
124.71 ± 3.37
−0.744
0.458
Day 7
81.93 ± 1.63
87.48 ± 1.29
−21.421
≤0.001
Week 12
67.52 ± 4.85
76.17 ± 3.10
−12.104
≤0.001
VWF, ng/mL
Baseline
207.55 ± 7.77
207.06 ± 7.64
0.363
0.717
Day 7
192.33 ± 3.79
195.69 ± 3.79
−5.041
≤0.001
Week 12
179.89 ± 5.09
185.82 ± 3.52
−7.714
≤0.001
Equal variance, analyzed by Levene’s test for equality of variances ; and values were, respectively, statistics and probability which were analyzed by paired -test for the two groups before treatment.
